Strongbridge Biopharma (NASDAQ:SBBP) Research Coverage Started at Cantor Fitzgerald

Stock analysts at Cantor Fitzgerald began coverage on shares of Strongbridge Biopharma (NASDAQ:SBBP) in a research report issued on Tuesday, December 5th, Marketbeat Ratings reports. The firm set a “buy” rating and a $14.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 93.10% from the company’s previous close.

The analysts wrote, “Right Team in Place. Following challenges faced by Taro Pharmaceuticals (TARO – NC) in commercializing KEVEYIS, we believe Strongbridge is well equipped to conduct a successful re-launch. The management team brings experience from an array of blue chip commercial pharmaceutical corporations: Shire (SHPG – OW, by Cantor Analyst Louise Chen), Bristol-Myers Squibb (BMY – NC), Johnson & Johnson(JNJ – NC), and Eli Lilly (LLY – NC). In addition to this critical know-how, Strongbridge has also hired an impressive sales force with experiences from orphan organizations such as Shire, Biomarin (BMRN – NC), and Retrophin (RTRX – NC).””

A number of other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, November 22nd. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a research note on Wednesday, November 15th. ValuEngine cut Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Oppenheimer began coverage on Strongbridge Biopharma in a report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $12.81.

Shares of Strongbridge Biopharma (NASDAQ:SBBP) traded up $0.45 during trading on Tuesday, hitting $7.25. 190,983 shares of the stock traded hands, compared to its average volume of 168,643. The firm has a market capitalization of $288.64 and a P/E ratio of -2.14. The company has a debt-to-equity ratio of -1.89, a quick ratio of 4.61 and a current ratio of 4.70. Strongbridge Biopharma has a twelve month low of $2.00 and a twelve month high of $8.85.

Large investors have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board acquired a new position in Strongbridge Biopharma during the 2nd quarter worth approximately $114,000. Rhumbline Advisers bought a new position in Strongbridge Biopharma during the 2nd quarter worth $154,000. California State Teachers Retirement System bought a new position in Strongbridge Biopharma during the 2nd quarter worth $277,000. Teachers Advisors LLC bought a new position in Strongbridge Biopharma during the 2nd quarter worth $297,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Strongbridge Biopharma during the 2nd quarter worth $331,000. 57.53% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Strongbridge Biopharma (NASDAQ:SBBP) Research Coverage Started at Cantor Fitzgerald” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://weekherald.com/2017/12/30/cantor-fitzgerald-initiates-coverage-on-strongbridge-biopharma-sbbp.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply